<DOC>
	<DOC>NCT00655044</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.</brief_summary>
	<brief_title>Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 1 diabetes Type 2 diabetes Candidates of use of a basal insulin as part of their diabetes regimen Unwilling to adhere to therapy or follow up Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>